Artiva Biotherapeutics, Inc. ARTV · Stock Open Artiva Biotherapeutics, Inc. in new tab
Artiva Biotherapeutics, Inc. Analysis (ARTV)
Is Artiva Biotherapeutics, Inc. a good investment? Artiva Biotherapeutics, Inc. (ARTV) is currently trading at 10.76 USD. Market analysts have a consensus price target of 35.80 USD. This suggests a potential upside from current levels.
Earnings Schedule: Artiva Biotherapeutics, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -2.82.
Investor FAQ
Does Artiva Biotherapeutics, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Artiva Biotherapeutics, Inc.?
Artiva Biotherapeutics, Inc. is classified as a Stock.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -3.55.
Company Profile
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma. The company also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 targeting chimeric antigen receptor (CAR)-NK cell product candidate for the treatment of various solid tumors, such as breast, gastric and esophageal, and bladder cancers; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate for the treatment of hematological malignancies. Artiva Biotherapeutics, Inc. was incorporated in 2019 and is headquartered in San Diego, California.
Community Discussion